Wave Life Sciences, Inc. (NasdaqGM: WVE)
Health Care · Pharmaceuticals · US
$5.25
-0.76% today · -46.8% 1Y
Wave Life Sciences, Inc. (NasdaqGM: WVE) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.04B and employs 317 people.
Over the last twelve months the share price has lost 46.8%, trading between 5.01 and 21.73.
Tweenvest scores Wave Life Sciences, Inc. across four factors: quality 28/100, value 39/100, growth 52/100. Its strongest factor is growth.
WVE price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.04B
- Revenue (TTM)
- $65.37M
- P/E
- —
- EPS
- -1.08
- Dividend yield
- —
- Beta (5Y)
- -1.29
- 52-week high
- $21.73
- 52-week low
- $5.01
- Avg volume (3M)
- —
- Shares outstanding
- 197.05M
- Employees
- 317
- Next earnings
- —
About Wave Life Sciences, Inc.
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
- ISIN
- US94352A1043
- Founded
- 2012
- Listed since
- Nov 11, 2015
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,235.36 | +0.14% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.50 | +0.13% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $155.85 | -0.38% |
| Roche Holding AGSWX: ROP | $371.62B | CHF370.90 | -0.78% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £123.18 | -1.27% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.51 | -0.21% |
Figures last refreshed Aug 18, 2026.